These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32530065)

  • 1. A shift of dynamic equilibrium between the KIT active and inactive states causes drug resistance.
    Srikakulam SK; Bastys T; Kalinina OV
    Proteins; 2020 Nov; 88(11):1434-1446. PubMed ID: 32530065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of D816X mutation-induced c-Kit activation and -mediated inhibitor resistance in gastrointestinal stromal tumor.
    Jiang H; Shao W; Wang Y; Xu R; Zhou L; Mu X
    J Mol Graph Model; 2018 Sep; 84():189-196. PubMed ID: 30015051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms.
    Laine E; Chauvot de Beauchêne I; Perahia D; Auclair C; Tchertanov L
    PLoS Comput Biol; 2011 Jun; 7(6):e1002068. PubMed ID: 21698178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic drug selectivity between wild-type and mutant BRaf kinases in colon cancer.
    Zhang J; Ji T
    J Mol Model; 2017 Jan; 23(1):1. PubMed ID: 27921184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.
    DiNitto JP; Deshmukh GD; Zhang Y; Jacques SL; Coli R; Worrall JW; Diehl W; English JM; Wu JC
    J Biochem; 2010 Apr; 147(4):601-9. PubMed ID: 20147452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.
    Foster R; Griffith R; Ferrao P; Ashman L
    J Mol Graph Model; 2004 Oct; 23(2):139-52. PubMed ID: 15363456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of CSF-1R D802V and KIT D816V homologous mutations on receptor tertiary structure and allosteric communication.
    Da Silva Figueiredo Celestino Gomes P; Panel N; Laine E; Pascutti PG; Solary E; Tchertanov L
    PLoS One; 2014; 9(5):e97519. PubMed ID: 24828813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
    Roskoski R
    Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
    Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
    Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Modeling Study of c-KIT/PDGFRα Dual Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
    Keretsu S; Ghosh S; Cho SJ
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.
    Apsel Winger B; Cortopassi WA; Garrido Ruiz D; Ding L; Jang K; Leyte-Vidal A; Zhang N; Esteve-Puig R; Jacobson MP; Shah NP
    Cancer Res; 2019 Aug; 79(16):4283-4292. PubMed ID: 31270078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of novel
    Elasbali AM; Al-Soud WA; Elfaki EM; Alanazi HH; Alharbi B; Alharethi SH; Anwer K; Mohammad T; Hassan MI
    J Biomol Struct Dyn; 2024 Jul; 42(11):5982-5994. PubMed ID: 37403288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight.
    Purohit R
    J Biomol Struct Dyn; 2014; 32(7):1033-46. PubMed ID: 23782055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor.
    Roskoski R
    Biochem Biophys Res Commun; 2005 Dec; 338(3):1307-15. PubMed ID: 16226710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.
    Chan PM; Ilangumaran S; La Rose J; Chakrabartty A; Rottapel R
    Mol Cell Biol; 2003 May; 23(9):3067-78. PubMed ID: 12697809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cotargeting signaling pathways driving survival and cell cycle circumvents resistance to Kit inhibitors in leukemia.
    Buet D; Gallais I; Lauret E; Denis N; Lombard B; Guillonneau F; Kosmider O; Loew D; Dusanter-Fourt I; Guillouf C; Mayeux P; Moreau-Gachelin F
    Blood; 2012 May; 119(18):4228-41. PubMed ID: 22438255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
    Zhu MJ; Ou WB; Fletcher CD; Cohen PS; Demetri GD; Fletcher JA
    Oncogene; 2007 Sep; 26(44):6386-95. PubMed ID: 17452978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation.
    Tamirat MZ; Koivu M; Elenius K; Johnson MS
    PLoS One; 2019; 14(9):e0222814. PubMed ID: 31536605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl.
    Healy EF; Johnson S; Hauser CR; King PJ
    FEBS Lett; 2009 Sep; 583(17):2899-906. PubMed ID: 19660459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.